Next Article in Journal
3D-Powder-Bed-Printed Pharmaceutical Drug Product Tablets for Use in Clinical Studies
Previous Article in Journal
Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Nguyen et al. Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics 2022, 14, 299

1
ARNA, Inserm U1212, CNRS 5320, University of Bordeaux, 146 Rue Léo Saignat, CEDEX, 33076 Bordeaux, France
2
UMR 5026, University of Bordeaux, CNRS, Bordeaux-INP, ICMCB, 87 Avenue du Dr Albert Schweitzer, CEDEX, 33608 Pessac, France
3
MFP, CNRS 5234, University of Bordeaux, 146 Rue Léo Saignat, CEDEX, 33076 Bordeaux, France
*
Author to whom correspondence should be addressed.
Pharmaceutics 2022, 14(11), 2317; https://doi.org/10.3390/pharmaceutics14112317
Submission received: 20 October 2022 / Accepted: 24 October 2022 / Published: 28 October 2022

Error in Figure

In the original publication [1], there was a mistake in Figure 1 as published. The chemical formulae of nucleolipids, i.e., DOTAU and diC16dT, did not display correctly, as the repeats of carbon atoms in the lipid chain (parenthesis and number of repeats) were missing. The corrected Figure 1 appears below. The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated. Pharmaceutics 14 02317 i001

Reference

  1. Nguyen, P.V.; Aubry, C.; Boudaoud, N.; Gaubert, A.; Langlois, M.-H.; Marchivie, M.; Gaudin, K.; Arpin, C.; Barthélémy, P.; Kauss, T. Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics 2022, 14, 299. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Nguyen, P.V.; Aubry, C.; Boudaoud, N.; Gaubert, A.; Langlois, M.-H.; Marchivie, M.; Gaudin, K.; Arpin, C.; Barthélémy, P.; Kauss, T. Correction: Nguyen et al. Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics 2022, 14, 299. Pharmaceutics 2022, 14, 2317. https://doi.org/10.3390/pharmaceutics14112317

AMA Style

Nguyen PV, Aubry C, Boudaoud N, Gaubert A, Langlois M-H, Marchivie M, Gaudin K, Arpin C, Barthélémy P, Kauss T. Correction: Nguyen et al. Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics 2022, 14, 299. Pharmaceutics. 2022; 14(11):2317. https://doi.org/10.3390/pharmaceutics14112317

Chicago/Turabian Style

Nguyen, Phuoc Vinh, Clémentine Aubry, Narimane Boudaoud, Alexandra Gaubert, Marie-Hélène Langlois, Mathieu Marchivie, Karen Gaudin, Corinne Arpin, Philippe Barthélémy, and Tina Kauss. 2022. "Correction: Nguyen et al. Oligonucleotide Solid Nucleolipid Nanoparticles against Antibiotic Resistance of ESBL-Producing Bacteria. Pharmaceutics 2022, 14, 299" Pharmaceutics 14, no. 11: 2317. https://doi.org/10.3390/pharmaceutics14112317

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop